Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma

NCT02139397 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT02139397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02139397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 1/2
Overall status
Completed
Start date
June 6, 2014
Completion date
January 19, 2024
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma recurrent